We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Halozyme Therapeutics (HALO) Could Be Positioned for a Surge
Read MoreHide Full Article
Halozyme Therapeutics, Inc. (HALO - Free Report) is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on HALO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that HALO International could be a solid choice for investors.
Current Quarter Estimates for HALO
In the past 30 days, three estimates have gone higher for Halozyme while none has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 56 cents a share 30 days ago, to 71 cents a share today, a move of 26.8%.
Current Year Estimates for HALO
Meanwhile, Halozyme’s current year figures are also looking quite promising, with three estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 17 cents per share 30 days ago to 32 cents per share today, a move of 88.2%.
The stock has also started to move higher lately, adding 14% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
Why Halozyme Therapeutics (HALO) Could Be Positioned for a Surge
Halozyme Therapeutics, Inc. (HALO - Free Report) is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on HALO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that HALO International could be a solid choice for investors.
Current Quarter Estimates for HALO
In the past 30 days, three estimates have gone higher for Halozyme while none has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 56 cents a share 30 days ago, to 71 cents a share today, a move of 26.8%.
Current Year Estimates for HALO
Meanwhile, Halozyme’s current year figures are also looking quite promising, with three estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 17 cents per share 30 days ago to 32 cents per share today, a move of 88.2%.
FirstEnergy Corporation Price and Consensus
FirstEnergy Corporation Price and Consensus | FirstEnergy Corporation Quote
Bottom Line
The stock has also started to move higher lately, adding 14% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>